A phase 2 study of BX211 analyzing safety, tolerability, and efficacy in Diabetic Foot Osteomyelitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Mar 2025 According to a BiomX media release, company announced Following the successful Phase 2 readout of BX211, the Company is planning for a Phase 2/3 trial, pending discussions and feedback from the U.S Food and Drug Administration
31 Mar 2025 According to a BiomX media release, Primary endpoint(sustained reduction of ulcer size(PAR) of study ulcer through week 13) has been met.
31 Mar 2025 According to a BiomX media release, company announced positive, topline safety and efficacy results from the Companys DFO Adaptive Novel Care Evaluation Phase 2 trial evaluating its BX211 phage treatment for DFO

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com